Dr. Reddy's Laboratories launches Imatinib Mesylate Tablets, USP in the U.S. Market
Deepthi | Myequity news | Date : 01-10-2018 9:40:00 IST
Dr. Reddy's Laboratories Ltd. today launched the Imatinib Mesylate Tablets, USP, a therapeutic equivalent generic version of Gleevec (imatinib mesylate) Tablets in the United States market approved by the U.S. Food and Drug Administration (USFDA).
The Gleevec brand and generic had U.S. sales of approximately $868 million MAT for the most recent twelve months ending in July 2018 according to IMS Health.
Dr. Reddy's Imatinib Mesylate Tablets, USP is available in 100 mg 30 count bottle size and 400 mg 90 count bottle size.
About Dr. Reddy's:
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APls, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe.